SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease by unknown
Brinkmalm et al. Molecular Neurodegeneration 2014, 9:53
http://www.molecularneurodegeneration.com/content/9/1/53RESEARCH ARTICLE Open AccessSNAP-25 is a promising novel cerebrospinal fluid
biomarker for synapse degeneration in
Alzheimer’s disease
Ann Brinkmalm1*, Gunnar Brinkmalm1, William G Honer2, Lutz Frölich3, Lucrezia Hausner3, Lennart Minthon4,5,
Oskar Hansson4,5, Anders Wallin1, Henrik Zetterberg1,6, Kaj Blennow1 and Annika Öhrfelt1Abstract
Background: Synaptic degeneration is an early pathogenic event in Alzheimer’s disease, associated with cognitive
impairment and disease progression. Cerebrospinal fluid biomarkers reflecting synaptic integrity would be highly
valuable tools to monitor synaptic degeneration directly in patients. We previously showed that synaptic proteins
such as synaptotagmin and synaptosomal-associated protein 25 (SNAP-25) could be detected in pooled samples of
cerebrospinal fluid, however these assays were not sensitive enough for individual samples.
Results: We report a new strategy to study synaptic pathology by using affinity purification and mass spectrometry
to measure the levels of the presynaptic protein SNAP-25 in cerebrospinal fluid. By applying this novel affinity mass
spectrometry strategy on three separate cohorts of patients, the value of SNAP-25 as a cerebrospinal fluid biomarker
for synaptic integrity in Alzheimer’s disease was assessed for the first time. We found significantly higher levels of
cerebrospinal fluid SNAP-25 fragments in Alzheimer’s disease, even in the very early stages, in three separate
cohorts. Cerebrospinal fluid SNAP-25 differentiated Alzheimer’s disease from controls with area under the curve of
0.901 (P < 0.0001).
Conclusions: We developed a sensitive method to analyze SNAP-25 levels in individual CSF samples that to our
knowledge was not possible previously. Our results support the notion that synaptic biomarkers may be important
tools for early diagnosis, assessment of disease progression, and to monitor drug effects in treatment trials.
Keywords: Alzheimer’s disease, Biomarker, Cerebrospinal fluid, SNAP-25, SNARE proteins, Mass spectrometry,
Immunopurification, Selected reaction monitoringBackground
Animal models of the early phases of Alzheimer’s disease
have directly demonstrated loss of presynaptic proteins
and synaptic dysfunction [1,2]. In patients, however,
assays for presynaptic proteins are indirect or rely on
post-mortem findings. In the early stages of disease they
have provided inconsistent results reporting elevated, un-
changed, and lower protein amounts [3-12]. Biomarker
studies of amyloidβ1-42 (Aβ1-42), total tau (T-tau) and
tau phosphorylated at threonine 181 (P-tau181) in cerebro-
spinal fluid (CSF) have contributed to understanding the* Correspondence: ann.brinkmalm@neuro.gu.se
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article, unless otherwise stated.sequence of clinically relevant molecular events contribut-
ing to cognitive impairment [13]. In the central nervous
system synaptosomal-associated protein 25 (SNAP-25) is
an important marker of functional synapses, being one
essential component of the soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNARE)
complex. These proteins mediate synaptic communication
by initiating fusion of synaptic vesicles [14].
The notions that synaptic loss occurs early in Alzheimer’s
disease, and that synaptic proteins at active synapses could
be biomarkers indicating the degree of synaptic degene-
ration have prompted interest in detecting relevant synap-
tic proteins in human biological fluid samples. Analysis of
synaptic proteins in CSF is complicated by the presence of
only trace amounts, and the membrane-bound nature oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cluding our own, have detected synaptic proteins in CSF
[16-21]. However, these studies were performed on rela-
tively large quantities of pooled CSF from multiple pa-
tients [16,17,21]. Moreover, the target proteins had to be
selectively purified and concentrated in several steps and
the quantitative aspects of the techniques may have been
sub-optimal [20].
Here, we have developed an assay where the concen-
tration of the presynaptic protein SNAP-25 could be
reproducibly measured in CSF samples from individual
patients. We hypothesized that soluble forms of brain
SNAP-25 were the most likely to resemble SNAP-25 in
CSF. Since SNAP-25 is abundant in brain tissue we used
biochemically fractionated human brain homogenate
(soluble, membrane-bound, and membrane-raft asso-
ciated protein fractions) to design a strategy for quan-
tification of SNAP-25 in CSF by combining selective
purification with immunoprecipitation, digestion with
trypsin, and mass spectrometry analysis. We found sig-
nificantly higher levels of SNAP-25 in CSF in Alzheimer’s
disease in three separate cohorts, including in the very
early stage of the disease.
Results
Characterization and quantification of SNAP-25 in human
brain tissue
We used the monoclonal antibodies to affinity purify
SNAP-25 from biochemically fractionated human brain
homogenate. Using the SP12 antibody and quantification
with selected reaction monitoring mass spectrometry
(SRM-MS) we compared the SNAP-25 levels in brain
homogenate fractions from Alzheimer’s disease patients
(N = 15) and age-matched controls (N = 15) (Additional
file 1: Table S1). We found that the levels of SNAP-25
were significantly lower in the Alzheimer’s disease group
for the membrane-bound and the membrane-raft asso-
ciated fractions (Figure 1A-B). In contrast, the levels of
SNAP-25 in the soluble protein fractions were very low or
undetectable (data not shown). However, when affinityFigure 1 Targeted SRM-MS analyses of SNAP-25 in human brain. Indiv
labeled peptide standard) of immunoprecipitated [antibodies SP12 (A-B) and
(A) and membrane-raft associated (B) and soluble (C), extract of superior pari
(N = 15). The lower, upper and middle lines of the error bars correspond to th
the extreme N-terminus of SNAP-25, especially when it’s N-terminal acetylatedpurifying with SMI81 instead of SP12, SNAP-25 could be
quantified in all soluble fractions (Figure 1C). Never-
theless, no significant differences between the levels of
soluble SNAP-25 in Alzheimer’s disease and control brain
homogenate samples were observed.
To investigate if the dissimilar levels of SP12- and
SMI81-immunoreactive SNAP-25 in the soluble fractions
could be due to a truncation or other post-translational
modifications we analyzed a subset of the samples with
LC-MS/MS. In the majority of the soluble fractions, only
tryptic peptides originating from the N-terminal part of
the SNAP-25 protein were detected (Figure 2), indicating
that the soluble SNAP-25 were C-terminally truncated.
However, in all the membrane-bound and membrane-raft
associated fractions the entire SNAP-25 protein was
detected (regardless of antibody) (Additional file 1:
Figure S1). Moreover, in all fractions, including the
soluble, SNAP-25 was N-terminally modified by me-
thionine excision and acetylation.
To characterize the soluble SNAP-25 forms we used a
top-down LC-MS/MS approach. Using undigested pro-
teins from the SMI81 affinity purified soluble fraction, we
successfully identified eight truncated forms of soluble
SNAP-25, all N-terminally modified by methionine exci-
sion and acetylation (Additional file 1: Figure S2, Table
S2). Building on the findings of the soluble truncated
SNAP-25 peptides we changed our approach to target
the furthermost N-terminal tryptic peptides of SNAP-25
(Figure 2B) and perform the MS-based quantification with
high resolution selected ion monitoring (HR-SIM-MS) on
a Quadrupole-Orbitrap Mass Spectrometer (Q Exactive)
[22]. The reproducibility of the novel method was mea-
sured and the CV of the SNAP-25 levels was found to be
less than 10% (Additional file 1: Table S3).
Evaluation of SNAP-25 as a synaptic marker in CSF
samples
Demographic results
Table 1 shows the demographic characteristics of the
groups. The German cohort was composed of nine patientsidual values for the SRM-MS measured ratios (endogenous peptide/
SMI81 (C) SNAP-25, in biochemically fractionated membrane-bound
etal gyrus from controls (N = 15) and patients with Alzheimer’s disease
e 25th and 75th percentiles and medians, respectively. SMI81 recognizes
. The exact epitope of SP12 is unknown.
Figure 2 Sequence coverage of SNAP-25. (A) Heat map for the relative LC-MS signal intensities of individual tryptic peptides from SNAP-25B.
Biochemically fractionated soluble proteins of superior parietal gyrus from controls (N = 7) and patients with Alzheimer’s disease (N = 9) were
immunoprecipitated with SMI81. High resolution LC-MS ion chromatograms of all peptides identified as belonging to SNAP-25B were extracted.
An increase of signal intensity is seen as a blue to red shift. (B) Amino acid sequences for SNAP-25B and SNAP-25A. Soluble endogenous forms
identified by top-down LC-MS/MS analysis are indicated by arrows above the sequences. Differences between SNAP-25B and SNAP-25A are
indicated by boxes. Amino acids belonging to tryptic peptides identified by LC-MS/MS are labeled bold. The two glutamines (Q) indicated “ionic
0 layer” contribute together with a syntaxin glutamine (Q), and a VAMP arginine (R) to the highly conserved 3Q:1R motif at the core of the
SNARE complex.
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years), seven subjects with prodromal Alzheimer’s disease
(four men and three women, 57-77 years), and nine non-
demented controls (two men and seven women, 60-83
years). The first replication set (Swedish cohort I) was com-
posed of 10 patients with Alzheimer’s disease (three men
and seven women, 59-84 years), and six non-demented
controls (one man and five women, 47-64 years). The sec-
ond replication set (Swedish cohort II) was composed of 17
patients with Alzheimer’s disease (five men and 12 women,
61-76 years), and 17 healthy controls (nine men and eight
women, 63-70 years). The patients and controls in the
German and Swedish cohort II were age-matched, while
the patients with Alzheimer’s disease were significantlyolder than the controls in the Swedish cohort I. In all three
cohorts, patients with Alzheimer’s disease had a signifi-
cantly lower MMSE score compared with the controls.
Levels of SNAP-25 in CSF
The CSF levels of all three investigated tryptic peptides of
SNAP-25 were significantly higher in patients with pro-
dromal Alzheimer’s disease and overt Alzheimer’s disease
compared with non-demented controls (Figure 3A-C).
Moreover, two of the SNAP-25 peptides (amino acids
17-31 and 32-40) were significantly higher in Alzheimer’s
disease compared with prodromal Alzheimer’s disease
(Figure 3B-C). Consistently, the CSF levels of all tryptic
peptides of SNAP-25 were significantly higher in patients
Table 1 Demographic data and biomarker CSF levels for the diagnostic groupsa
German cohort Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 9 (2/7) 7 (4/3) 9 (3/6)
Age (years) 70 (68-74) 72 (69-73) 68 (68-79)
MMSE 27 (25-29) 28 (27-28) 22 (21-23) P = 0.02b, P = 0.001c
Aβ1-42 (ng/L) 1065 (797-1201) 541 (521-753) P = 0.005b 524 (424-695) P = 0.0005b
T-tau (ng/L) 165 (135-208) 403 (353-513) P = 0.0002b 779 (683-864) P = 0.00004b, P = 0.002c
P-tau181 (ng/L) 45 (38-50) 81 (76-95) P = 0.0002
b 130 (108-161) P = 0.00004b, P = 0.005c
Swedish cohort I Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 6 (1/5) 10 (3/7)
Age (years) 54 (48-63) 77 (73-82) P = 0.001b
MMSE 27 (27-28) 24 (22-25) P = 0.0003b
Aβ1-42 (ng/L) 915 (860-1040) 470 (355-560) P = 0.0003b
T-tau (ng/L) 290 (230-300) 690 (590-1100) P = 0.0002b
P-tau181 (ng/L) 56 (40-60) 92 (84-132) P = 0.0003
b
Swedish cohort II Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 17 (9/8) 17 (5/12)
Age (years) 66 (64-68) 68 (66-70)
MMSE 30 (29-30) 25 (24-27) P < 0.0001b
Aβ1-42 (ng/L) 640 (530-870) 320 (210-440) P = 0.0001b
T-tau (ng/L) 250 (180-320) 560 (360-1020) P = 0.0006b
P-tau181 (ng/L) 46 (34-58) 93 (54-127) P = 0.001
b
Abbreviations: Aβ1-42 (amyloidβ 1-42), CSF (cerebrospinal fluid), MMSE (mini-mental state examination), T-tau (total tau), P-tau181 (tau phosphorylated at
threonine 181).
aData are given as median (interquartile range) unless otherwise indicated. Statistical differences were determined using nonparametric tests.
bCompared with controls.
cCompared with prodromal Alzheimer’s disease.
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controls in the replication set (Figure 3D-F). In the second
replication set, the CSF levels of the tryptic peptide of
SNAP-25 (32-40) were significantly higher in patients
with Alzheimer’s disease compared with healthy controls
(Figure 3I).
There were no cohort effects on the CSF levels of
novel SNAP-25 biomarkers, P-tau181 or Aβ1-42 (data
not shown), allowing statistical analyses of the entire
group of participant samples from Alzheimer’s disease
(N = 36) and controls (N = 32) (Figure 3J-L). The tryptic
peptide assays of SNAP-25 (32-40, 17-31, and Ac-2-16)
and CSF biomarkers (Aβ1-42, T-tau and P-tau181) could
each differentiate Alzheimer’s disease (N = 36) from con-
trols (N = 32), with area under the curve of 0.901 (0.828-
0.974) (P < 0.0001), 0.808 (0.703-0.913) (P < 0.0001), 0.772
(0.659-0.885) (P < 0.001), 0.881 (0.802-0.960) (P < 0.0001),
0.933 (0.873-0.994) (P < 0.0001), and 0.916 (0.844-0.987)
(P < 0.0001), respectively (Figure 4).
No statistically significant correlations between age
and levels of the tryptic peptides of SNAP-25 (Ac-2-16,
17-31, and 32-40) were observed in either the control
group (N = 33) or the Alzheimer’s disease group (N = 36)
(Table 2). The MMSE score, indicating the severity ofcognitive impairment, correlated significantly with SNAP-25
(Ac-2-16) in the Alzheimer’s disease (N = 36) group
(Table 2). All tryptic peptides of SNAP-25 (Ac-2-16,
17-31, and 32-40) correlated with the levels of T-tau and
P-tau181 in both the control group (N = 33) and in patients
with Alzheimer’s disease (N = 36) (Table 2). The tryptic
peptides of SNAP-25 (Ac-2-16 and 17-31) correlated with
Aβ1-42 in the control group, but not in patients with
Alzheimer’s disease (Table 2).
Discussion
We report a new strategy to study synaptic pathology by
using affinity purification and quantitative mass spec-
trometry to measure levels of the presynaptic SNAP-25
in CSF samples from individual patients. This is the first
study demonstrating that SNAP-25 might be a useful
CSF biomarker in differential diagnosis of patients with
Alzheimer’s disease/prodromal Alzheimer’s disease from
controls and also in discriminating Alzheimer’s disease
from prodromal Alzheimer’s disease.
The novel CSF SNAP-25 assay was developed using
biochemically fractionated human brain homogenate
with high concentration of synaptic proteins. We found
that the levels of SNAP-25 were significantly lower in
Figure 3 (See legend on next page.)
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Figure 3 Targeted HR-SIM-MS analyses of SNAP-25 in human CSF. Individual values for the HR-SIM-MS measured peak area ratios ([endogenous
peptide/labeled peptide standard] multiplied by 10,000) of immunoprecipitated (SMI81 antibody) SNAP-25 in CSF samples within German cohort
(A-C), Swedish cohort I (D-F), Swedish cohort II (G-I), and the entire group of Alzheimer’s disease (N = 36) and controls (N = 32) (J-L). The nine panels
depict the measured levels of three N-terminal tryptic peptides of SNAP-25, Ac-2-16 (A, D, G, J), 17-31 (B, E, H, K), and 32-40 (C, F, I, L).
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the membrane-raft associated fractions. These results are
consistent with previous studies of SNAP-25 in Alzheimer’s
disease using different immunoassays [5,6,8,23,24] and
demonstrated that the method was sufficiently sensitive to
detect pathological changes in brain tissue samples from
individual patients.
The dissimilar levels of SP12- and SMI81-immunoreactive
SNAP-25 in the soluble fractions made us hypothesize
that soluble SNAP-25 may be truncated or modified com-
pared to membrane associated SNAP-25. We found that
only tryptic peptides originating from the N-terminal part
of the soluble SNAP-25 protein were detected. Moreover,
in all fractions, including the soluble, SNAP-25 was
N-terminally modified by methionine excision and acetyl-
ation, consistent with a previous study [25]. The existence
of a soluble N-terminal peptide fragment of SNAP-25 is
consistent with the observations that immunoprecipi-
tation with a monoclonal antibody directed towards the
N-terminal of SNAP-25 increases the yield.Figure 4 ROC curve analysis of SNAP-25 in human CSF. ROC
curve analysis for SNAP-25 32-40 (turquoise), SNAP-25 17-31 (green),
SNAP-25 Ac-2-16 (black) Aβ1-42 (orange), T-tau (purple) and P-tau181
(yellow) in CSF for differentiation of Alzheimer’s disease patients
from controls in the entire subject material. The area under the
curve (95% confidence interval) was 0.901 (0.828-0.974) (P < 0.0001),
0.808 (0.703-0.913) (P < 0.0001), 0.772 (0.659-0.885) (P < 0.001), 0.881
(0.802-0.960) (P < 0.0001), 0.933 (0.873-0.994) (P < 0.0001), and 0.916
(0.844-0.987) (P < 0.0001), respectively.Truncated soluble forms of SNAP-25 had never been
reported before and we characterized the various forms
with a top-down tandem MS approach. Undigested pro-
teins from the SMI81 affinity purified soluble fraction
were analyzed directly on LC-MS/MS. We successfully
identified eight truncated forms of soluble SNAP-25, all
N-terminally modified by methionine excision and acety-
lation. An interesting finding was that the potential clea-
vage site for the creation of the longest truncated form of
SNAP-25 (Ac-2-47) is located very close to the ionic
zero layer at the center of the SNARE complex [26,27]
(Figure 2B). However, the longest soluble SNAP-25 con-
tains the N-terminal amino acids 2-47 of the protein while
the two isoforms SNAP-25A and SNAP-25B differs in
amino acids 58, 60, 65, 69, 79, 84, and 88-89. Hence,
soluble SNAP-25 no longer contains information regar-
ding its original isoform (Figure 2B).
We found that the truncated forms of SNAP-25 were
present in CSF, and the level of the tryptic peptide of
SNAP-25 (32-40) was consistently and significantly higher
in patients with Alzheimer’s disease compared with con-
trols in the three independent cohorts. The tryptic peptide
assays of SNAP-25 (32-40, 17-31, and Ac-2-16) could each
differentiate Alzheimer’s disease from controls. However,
the tryptic peptide assay of SNAP-25 (32-40) provided a
slightly better differentiation of patients with Alzheimer’s
disease from controls compared with the tryptic assays of
SNAP-25 (Ac-2-16 and 17-31). The CSF levels of two of
the tryptic peptides of SNAP-25 (Ac-2-16 and 17-31) were
significantly higher in patients with Alzheimer’s disease
compared with controls in two of the three examined
clinical cohorts. Summarizing, these findings suggest
SNAP-25 (32-40) to provide the best differential diagnos-
tic biomarker of Alzheimer’s disease and showed differen-
tiation of patients with Alzheimer’s disease from controls
in a similar magnitude as the CSF biomarkers (Aβ1-42,
T-tau and P-tau181).
In the early stages of disease, synaptic markers in pre-
vious studies provided inconsistent results reporting ele-
vated, unchanged, and lower protein amounts [3-12]. In
the present study, CSF SNAP-25 peptides were already
increased in prodromal Alzheimer’s disease compared
with controls, supporting the notion that this synaptic
marker might provide an early marker for Alzheimer’s dis-
ease. Two of the SNAP-25 peptides (17-31 and 32-40)
could also be used to differentiate prodromal Alzheimer’s
disease and overt Alzheimer’s disease. A limitation of this
study is the small sample size for patients with mild
Table 2 Correlation between age, MMSE and biomarker levels in the entire CSF materiala
SNAP-25, Ac-2-16 SNAP-25, 17-31 SNAP-25, 32-40
Cont (N = 33)
Age N.S. N.S. N.S.
MMSE N.S. N.S. N.S.
Aβ1-42 rho = 0.560, P = 0.001 rho = 0.468, P = 0.007 N.S.
T-tau rho = 0.564, P = 0.001 rho = 0.563, P = 0.001 rho = 0.656, P = 0.0001
P-tau181 rho = 0.735, P < 0.0001 rho = 0.715, P < 0.0001 rho = 0.659, P < 0.0001
SNAP-25, Ac-2-16 - rho = 0.859, P < 0.0001 rho = 0.718, P < 0.0001
SNAP-25, 17-31 - - rho = 0.799, P < 0.0001
AD (N = 36)
Age N.S. N.S. N.S.
MMSE rho = -0.509, P = 0.002 N.S. N.S.
Aβ1-42 N.S. N.S. N.S.
T-tau rho = 0.557, P = 0.0004 rho = 0.732, P < 0.0001 rho = 0.824, P < 0.0001
P-tau181 rho = 0.717, P < 0.0001 rho = 0.808, P < 0.0001 rho = 0.835, P < 0.0001
SNAP-25, Ac-2-16 - rho = 0.836, P < 0.0001 rho = 0.720, P < 0.0001
SNAP-25, 17-31 - - rho = 0.900, P < 0.0001
Abbreviations: Aβ1-42 (amyloidβ 1-42), AD (Alzheimer’s disease), CSF (cerebrospinal fluid), MMSE (mini-mental state examination), T-tau (total tau), P-tau181
(tau phosphorylated at threonine 181).
aCorrelations presented by the Spearman’s rank correlation coefficient (rho). Non significant (N.S.) (P-value > 0.05) correlations were not reported.
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an early biomarker remains to be established.
The patients and controls in two of the cohorts were
age-matched, while the patients with Alzheimer’s disease
were significantly older than the controls in the Swedish
cohort I. However, no statistically significant correlations
between age and levels of the tryptic peptides of SNAP-25
(Ac-2-16, 17-31, and 32-40) in either the control group or
the Alzheimer’s disease group were observed, suggesting
that the detected SNAP-25 fragments not are influenced
by age.
To date there is no CSF biomarker available that
makes it possible to follow the progression of cognitive
decline. Previous studies suggest that synaptic loss corre-
lates with the clinical manifestations of Alzheimer’s dis-
ease, while there is no relation between the number of
accumulated parenchymal amyloid plaques and synaptic
pathology [3,4]. In the present study, there was a negative
correlation between SNAP-25 (Ac-2-16) and the MMSE,
indicating patients suffering from more severe cognitive
decline had higher levels of SNAP-25 (Ac-2-16), which
implies that the novel biomarker might be useful to follow
progression of cognitive decline. Interestingly, previous
studies have shown evidence that SNAP-25 single nu-
cleotide polymorphisms are associated with cognitive
decline [28,29].
The CSF level of T-tau generally reflects the intensity of
axonal and neuronal degeneration occurring in brain, while
P-tau181 serves as a more specific marker for Alzheimer’s
disease [30] CSF T-tau, P-tau181 and Aβ1-42 are stableover time making these Alzheimer’s biomarkers feasible
for monitoring biochemical effects in clinical trials [31].
The finding that all investigated SNAP-25 peptides corre-
lated well with T-tau and P-tau181, suggests that SNAP-25
might be a useful as a surrogate biomarker in future cli-
nical treatment studies with tau modifying drugs [32].
Conclusions
In summary, we have developed an assay allowing repro-
ducible measurement of the level of the presynaptic pro-
tein SNAP-25 in CSF samples from individual patients.
We demonstrate significantly higher levels of SNAP-25 in
CSF samples from patients with prodromal Alzheimer’s
disease and Alzheimer’s disease compared with controls.
Our results show that SNAP-25 is a promising novel CSF
biomarker for synapse degeneration in Alzheimer’s dis-
ease. This finding could be important for earlier diagnosis,
assessment of progression of disease and to monitor drug
effects in treatment trials in neurodegenerative diseases.
We also report the identification of previously unknown,
truncated soluble forms of SNAP-25 that could be
employed to study the dynamics of SNARE protein pro-
cessing and recycling.
Methods
Human brain tissue samples
The study included autopsy-confirmed patients with
Alzheimer’s disease (N = 15) and age-matched controls
(N = 15). Brain tissues from the region superior parietal
gyrus were analyzed. All brain tissues were obtained
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criteria, which are based on the distribution of neuro-
fibrillary tangles, were used to categorize the stage of
Alzheimer’s disease [33]. All Alzheimer’s disease patients
fulfilled Braak stages 5 or 6, while the controls fulfilled
Braak stages 0 or 1. Additional file 1: Table S1 shows the
clinical and demographic characteristics of the groups.
CSF samples
The exploratory phase of the investigation was performed
on pooled decoded CSF samples supplied by the Clinical
Neurochemistry Laboratory, Sahlgrenska University Hos-
pital Sweden, from patients who underwent lumbar punc-
ture to exclude infectious disorders of the central nervous
system.
The German cohort
CSF samples were obtained at the Interdisciplinary Me-
mory Clinic of the Department of Geriatric Psychiatry of
the Clinic of Psychiatry at the Central Institute of Mental
Health, Mannheim from subjects with Alzheimer’s disease
(N = 9), prodromal Alzheimer’s disease (N = 7) and non-
demented controls (N = 9) (Table 1). Alzheimer’s disease
was diagnosed according to the NINCDS-ADRDA cri-
teria, with all Alzheimer’s disease patients fulfilling the
criteria for probable Alzheimer’s disease [34]. Mild cogni-
tive impairment due to Alzheimer’s disease was diagnosed
according the new research criteria of Albert et al in 2011
[35]. Mild cognitive impairment was considered due to
prodromal Alzheimer’s disease if additionally, biomarkers
of molecular neuropathology of Alzheimer’s disease in
CSF were measured positively for Alzheimer’s disease
(CSF biomarkers Aβ1-42 ≤450 ng/L; T-tau ≥450 ng/L;
P-tau181 ≥61 ng/L) or if there was hippocampal volume
reduction or medial temporal atrophy assessed by visual
rating (Schelten’s scale >2) measured by an experienced
neuroradiologist. Non-demented controls had various
psychiatric diagnoses, (including geriatric depression, and
schizophrenia), Lumbar puncture in these patients was
carried out for clinical indications, such as excluding or-
ganic brain disorder. All were found normal on cognitive
screening tests, all routine CSF analyses were within nor-
mal limits and none of the CSF biomarkers were positive
for Alzheimer’s disease.
The Swedish cohort I
CSF samples were obtained at the Memory Clinic at
Skåne University Hospital in Malmö from subjects with
Alzheimer’s disease (N = 10) and non-demented controls
(N = 6) (Table 1). Subjects diagnosed with Alzheimer’s dis-
ease met the DSM-III-R criteria for dementia [36] and the
criteria for probable Alzheimer’s disease, as defined by
NINCDS-ADRDA [34]. The non-demented cases exhi-
bited cognitive complaints, but did not fulfil the criteriafor dementia. To rule out preclinical Alzheimer’s disease
in the latter group we only included cases with normal
CSF Aβ1-42 > 550 ng/L and T-tau <400 ng/L levels.
The Swedish cohort II
CSF samples from subjects with Alzheimer’s disease
(N = 17) and healthy controls (N = 17) were obtained
from the Gothenburg mild cognitive impairment study
for which the diagnostic procedure was described in de-
tail previously [37] (Table 1). The diagnosis of dementia
was based on the DSM-III-R criteria [36] together with
the criteria of NINCDS-ADRDA [34] and ICD-10 [38]
with regard to Alzheimer’s disease. Controls were not in-
cluded if they had subjective or objective signs of a cog-
nitive disorder.
CSF collection
All CSF samples were obtained by lumbar puncture
though the L3/L4 interspace. The CSF samples were
centrifuged at 2,000 g for 10 min at room tempera-
ture to remove cells and debris, and stored in aliquots
at –80°C pending biochemical analysis.
Homogenization of brain tissue
The brain extraction procedure was performed as de-
scribed by Öhrfelt et al. with minor modifications [39].
Briefly, 100 ± 10 mg of brain tissue was homogenized on
ice in 1 mL Tris- hydrochloride buffer (10 mM Tris-HCl,
pH 6.8) containing complete protease inhibitor (Roche
Diagnostics GmBH). Centrifugation of the homogenate
was performed at 31,000 g for 1 h at +4°C and the super-
natant was collected (Tris fraction, i.e., soluble fraction).
One milliliter of Tris-buffer containing 0.5% Triton X-100
(Union Carbide Corporation) with complete protease in-
hibitor was added, and the pellet was homogenized on ice
and sonicated using a micro-probe sonicator. The cen-
trifugation step was repeated and the supernatant was
collected (0.5% Triton fraction, i.e., membrane-bound
fraction). The same procedure was repeated by addition of
Tris-buffer containing 2% Triton (2% Triton fraction)
and complete protease inhibitor, and again by addition
of Tris-buffer containing 0.5% sodium dodecyl sulphate
and complete protease inhibitor for a final centrifuga-
tion at +12°C (SDS fraction, i.e., membrane-raft asso-
ciated fraction). All supernatants were aliquoted and
stored at –80°C pending analysis. For protein quantita-
tion, Protein DC assay (Bio-Rad Laboratories) reagent
was used. This reagent contains a reducing agent and is
detergent compatible.
Analysis of CSF biomarkers
The CSF analyses on Aβ1-42, T-tau and P-tau181 levels
were performed using commercially available assays from
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hTAU Ag and INNOTEST® PHOSPHO-TAU(181P).
Antibodies and recombinant protein of SNAP-25
The following antibodies were used: mouse monoclonal
antibody SP12 recognizing SNAP-25 [40,41] and mouse
monoclonal antibody SMI81 (Covance) against SNAP-25
[25]. The SMI81 antibody recognizes an epitope contai-
ning the N-terminally acetylated first 11 amino acids of
brain SNAP-25 [25]. Recombinant standard protein of
SNAP-25 was purchased from Origene.
Immunoprecipitation
The immunoprecipitation method for brain tissue extracts
and CSF samples was performed according to Öhrfelt
et al. with minor modifications [39]. Briefly, an aliquot
(1 μg) of the mouse monoclonal antibody SP12 (1 g/L) or
the mouse monoclonal antibody SMI81 (1 g/L) or IgG from
murine serum (1 g/L, Sigma-Aldrich) (a negative control),
was separately added to 100 μL magnetic Dynabeads
M-280 Sheep anti-mouse IgG (Invitrogen Corporation) and
incubated 1 h on a rocking platform at room temperature.
The beads were washed three times with 1 mL of PBS
(10 mM Na-phosphate, 0.15 M NaCl, pH 7.4). The
antibodies were cross-linked using 20 mM dimethyl pimeli-
midate dihydrochloride (Sigma-Aldrich) and 0.2 M trie-
thanolamine (pH 8.2 Sigma-Aldrich) according to the
manufacturer’s product description. The cross-linked beads
were washed two times in PBS and were blocked with Roti-
Block (Carl Roth) for 1 h on a rocking platform at room
temperature. Each brain tissue extract (soluble, membrane-
bound, and membrane-raft associated proteins) (26 μg of
total protein) and CSF samples (German cohort, 890 μL;
Swedish cohort I, 700 μL; Swedish cohort II, 600 μL) were
adjusted with 20% Triton and PBS to a final concentration
of 0.2% Triton and a final volume of 1 mL). Samples and
magnetic beads were incubated overnight on a rocking plat-
form at +4°C. The magnetic beads/sample solution was
transferred to the KingFisher magnetic particle processor
(Thermo Fisher Scientific), tube 1. The following three
wash steps (tubes 2-4) were conducted for 10 s in 1 mL of
each washing buffer: (tube 2) 0.025% Tween 20 in PBS,
(tube 3) PBS and (tube 4) 50 mM ammonium hydrogen
carbonate (NH4HCO3, pH 8.0). SNAP-25 was then eluted
from the beads by adding 100 μL 0.5% formic acid (FA)
(tube 5) for 4 min. The eluted fractions were transferred to
0.5 mL Protein LoBind Tube (Eppendorf AG) and dried in
a vacuum centrifuge.
Protein digestion and addition of heavy-isotope labeled
peptide standards
Brain tissue
The dried immunoprecipitated brain tissue samples were
dissolved in 10 μL 0.1% RapiGest SF Surfactant (Waters)in 50 mM NH4HCO3 1 h in room temperature. Disulfide
bonds were reduced by addition of 10 μL 10 mM dithio-
threitol (Sigma-Aldrich) in 50 mM NH4HCO3 and incu-
bation for 3 min at +90°C. After cooling to room
temperature, 5 μL 10 mM iodoacetamide (Sigma-Aldrich)
in 50 mM NH4HCO3 was added, and the samples were
incubated in the dark at room temperature for 30 min.
Digestion was carried out by adding 5 μL trypsin solution
(1 μg Sequencing Grade Modified Trypsin [Promega] dis-
solved in 0.01% aqueous HCl [0.1 g/L] and diluted to
5 mg/L in 50 mM NH4HCO3) and incubating overnight
at +37°C. To reduce the amount of RapiGest SF Surfactant
in the samples 2 μL 10% aqueous trifluoroacetic acid was
added (resulting in pH <2). The samples were incubated
45 min at +37°C and then centrifuged (16,900 g, 10 min,
+4°C). Twenty-five microliters of the resulting supernatant
of each sample was carefully transferred to 0.5 mL Protein
LoBind Tubes (Eppendorf AG). A C-terminally isoto-
pically labeled peptide, containing U-13C6, U-15 N4-ar-
ginine [R] (aa 18-30, ADQLADESLEST[R]) was supplied
by Sigma-Aldrich at over 95% peptide purity as determined
by reversed phase HPLC. The peptide was dissolved and
diluted in 0.1% aqueous FA to a final concentration of
5 fmol/μL. A 25 μL aliquot of the reference peptide was
added to each immunoprecipitated brain homogenate
sample after digestion and centrifugation.
CSF
The dried immunoprecipitated CSF samples were dis-
solved in 5 μL of a mixture of five isotopically labeled pep-
tides, containing U-13C6, U-15 N4-arginine [R], U-13C6,
U-15 N1-leucine [L] or U-13C6, U-15 N2-lysine [K] and
common for the N-terminal part of both SNAP-25A
and SNAP-25B. The peptide standard supplied by Sigma
Aldrich (aa 18-30, see above) was mixed with four Heavy-
Peptide FasTrack 1 standards (Thermo Fisher Scientific)
(~0.5 mg dissolved in 1 mL MilliQ water) (aa Ac2-16,
AEDADMRNE[L]EEMQR; aa 17-31, RADQ[L]ADESLE
STRR; aa 18-31 ADQLADESLEST[R][R]; and aa 32-40
MLQLVEES[K]) and diluted in 50 mM NH4HCO3
to a final concentration of ~100 fmol/μL (aa 18-30)
and ~3 ng/μL (FasTrack 1 standards). Reduction of disul-
fide bonds (5 μL 10 mM dithiothreitol), alkylation (5 μL
10 mM iodoacetamide), and digestion (5 μL 5 mg/L
trypsin) were performed as described above. To stop the
enzymatic activity 4 μL 10% aqueous FA was added.
The samples were centrifuged (16,900 g, 10 min, +4°C)
and 20 μL of each sample was transferred to LC-vials
(SUN-SRi).
SRM-MS analysis of immunoprecipitated SNAP-25 from
brain tissue
Aliquots (25 μL) of the 1:1 mixtures of stable isotope-
labeled standard peptide and immunoprecipitated SNAP-25
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SRM-MS using an Accela 1250 pump (Thermo Fischer
Scientific) coupled to a triple quadrupole mass spectrom-
eter (TSQ Vantage, Thermo Fischer Scientific) with an
IonMax source and HESI-II electrospray probe (Thermo
Fischer Scientific). Mobile phases were 0.1% aqueous FA
(v/v) (A) and 0.1% FA in 84% ACN in water (v/v) (B).
Samples (20 μL) were loaded directly onto a Hypersil
Gold-C18 column, (length 50 mm, inner diameter
2.1 mm, particle size 5 μm [Thermo Fischer Scientific])
with 0.1% aqueous FA at 100 μL/min. After 2 min of
loading, the peptides were eluted off the column using
the following linear gradient steps: 0 min 0%B; 4 min
17%B; 12 min 23%B; 15 min 100%B. The global MS pa-
rameters were: positive ion mode; spray voltage 3.5 kV;
vaporizer temperature +350°C; sheath gas pressure
40 psi; auxiliary gas pressure 25 arbitrary units; capillary
temperature +350°C; collision gas pressure 1.9 mTorr.
Pinpoint software version 1.3.0 (Thermo Fischer Scientific)
was used for method optimization and data processing.
LC–MS/MS analysis of immunoprecipitated SNAP-25 from
brain tissue
Aliquots (25 μL) of the 1:1 mixtures of stable isotope
labeled standard peptide and immunoprecipitated
SNAP-25 protein were transferred to LC-vials (Waters)
and analyzed by LC-MS/MS. The LC-MS/MS spectra
were acquired with a electrospray–linear quadrupole
ion trap–Fourier transform ion cyclotron resonance
(ESI-LQIT–FTICR) mass spectrometer equipped with a
7 T magnet (LTQ FT Ultra, Thermo Fischer Scientific)
coupled to a multi-dimensional nanoflow chromato-
graphy system (Ettan MDLC, GE Healthcare). A Zorbax
300 SB-C18 trap column (length 5 mm, inner diameter
0.3 mm, particle size 5 μm [Agilent Technologies]) was
used for on-line desalting and a reversed phase Zorbax
300 SBC18 column (length 150 mm, inner diameter
0.075 mm, particle size 3.5 μm [Agilent Technologies])
was used for high-resolution separation. Mobile phases
were 0.1% aqueous FA (v/v) (A) and 0.1% FA in 84%
ACN in water (v/v) (B). The separation was performed
at a flow rate of approximately 250 nL/min by applying
a linear gradient of 0-60% B for 50 min. The LTQ FT
Ultra was set to acquire positive ions and operated in
the data-dependent mode, where a scan cycle consisted
of one full scan mass spectrum (m/z 350-1500) acquired
in the FTICR mode (resolution 25,000), followed by tan-
dem mass spectrometry (MS/MS) scans acquired in
LQIT mode using collision-induced dissociation (CID)
and wideband activation. Dynamic exclusion was en-
abled with repeat count 2 and exclusion duration 120 s.
Isolation width was 3 m/z units, and the normalized
collision energy to 35. Each scan consisted of three
microscans.Database search and bioinformatic analysis
Database searches were submitted to the in-house database
server by using Mascot Deamon 2.3.0 (Matrix Science).
Database search parameters were; database (UniProtKB_
Human 131030), taxonomy (Homo sapiens), enzyme
(trypsin), variable modifications (acetyl [N-term], oxida-
tion [M], Label:13C(6)15 N(2) [K], and Label:13C(6)15 N
(4) [R]), fixed modifications (Carbamidomethyl [C]), mass
values (monoisotopic), peptide mass tolerance (5 ppm),
fragment mass tolerance (0.5 Da), and max missed clea-
vages (2).
Quantification of high mass accuracy precursor ions
Peak detection and integration were performed using
DeCyder 2.0 (GE Healthcare) using processing parame-
ters as described in [42]. In-house developed software
(Sequence and PeakExtractor) was used for in silico di-
gestion and automatic peak mass matching.
Top-down-LC-MS/MS analysis of intact SNAP-25
fragments from brain tissue
Soluble SNAP-25 forms immunoprecipitated with SMI81
from three different brain homogenate fractions were
pooled in a 0.5 mL Protein LoBind Tube (Eppendorf AG)
and dried in a vacuum centrifuge. The sample was dis-
solved in 25 μL of 0.1% aqueous FA for 1 h and then cen-
trifuged (16,900 g, 10 min, +4°C). The LC-MS/MS spectra
were acquired with the Ettan MDLC/LTQ FT Ultra sys-
tem using the same LC settings and columns as for the
digested samples (see above). The LTQ FT Ultra was ope-
rated in data-dependent mode with a scan cycle consisting
of one full scan mass spectrum acquired in FTICR mode
(m/z 500-1,200, resolution 50,000), and one MS/MS scan
in FTICR mode (resolution 50,000) using CID. Each scan
consisted of three microscans. Isolation width was 7 m/z
units, and the normalized collision energy 35. To ensure
MS/MS acquisition for the peptides of interest, an in-
clusion mass list was utilized. Peak picking and charge
deconvolution of acquired spectra were performed using
Mascot Distiller (Matrix Science) with processing parame-
ters as described in [42]. Database search parameters were;
database (UniProtKB_Human 120809), taxonomy (Homo
sapiens), enzyme (none), variable modifications (oxidation
[M]), fixed modifications (acetyl [N-term], carbamido-
methyl [C]), mass values (monoisotopic), peptide mass tol-
erance (10 ppm), fragment mass tolerance (50 mmu), and
instrument type (FTICR CID Distiller, meaning only singly
charged fragment ions were considered in the database
search).
HR-SIM-MS analysis of immunoprecipitated SNAP-25
from CSF
High-resolution selected ion monitoring (HR-SIM) ana-
lyses were performed on a quadrupole–orbitrap mass
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coupled to an Ultimate 3000 chromatography system
(Thermo Fisher Scientific). The samples (15 μL) were
loaded directly onto a Hypersil Gold-C18 column, (see
SRM-MS analysis) with 0.1% aqueous FA at 100 μL/min.
Mobile phases were the same as in the SRM-MS analysis.
After 2 min of loading, the peptides were eluted off the
column using the following linear gradient steps: 0 min
0%B; 4 min 13%B; 30 min 17%B; 50 min 26%B; 52 min
90%B. The IonMax ion source settings were: spray vol-
tage, +4100 V; capillary temperature, +320°C; sheath gas
pressure, 25 arbitrary units; auxiliary gas pressure, 10 arbi-
trary units; and heater temperature, +300°C. The instru-
ment was set to acquire scheduled pairs of SIM scans and
subsequent all ion fragmentation scans in profile mode
allowing simultaneous detection of both the SNAP-25
peptide and the corresponding isotopically labeled peptide
standard. The settings were common for both scans types
and were as follows: resolution, 70,000; AGC target, 3e6;
maximum injection time, 300 ms. Data acquisition and
analysis were performed with Xcalibar software version
2.2 SP1.48 (Thermo Fisher Scientific) and Pinpoint 1.3.0.
SNAP-25 levels for the different tryptic peptides were
compensated for the different CSF volumes and reported
as the ratio between the peak areas of the endogenous
peptide and the labeled peptide standard multiplied by
10,000.
Investigation of reproducibility
Approximately 5 pmol each of two isotopically labeled N-
terminal SNAP-25 peptides (aa Ac2-16, AEDADM[R]
NELEEMQ[R] and aa Ac2-20 AEDADMRNE[L]EEMQR
RADQ, FasTrack 1 [Thermo Fisher Scientific]) were
added to 15 mL CSF. The spiked CSF pool was divided
into 890 μL aliquots, immunoprecipitated with SMI81
and digested as described above. HR-SIM-MS analysis of
eight of the samples was performed on 8 μL injec-
tions. The CV of the measured levels was less than 10%
(Additional file 1: Table S3).
Statistical analysis
Because the distributions of most analytes were not
normal (Shapiro-Wilk test, P <0.05), non-parametric sta-
tistics were used for analysis. Data are given as median
(inter-quartile range). Differences between more than two
groups were assessed with Kruskal-Wallis test. Statistically
significant results (P < 0.05) were followed by Mann-
Whitney U-tests to investigate group differences. Since
there were no significant alterations of the levels of novel
SNAP-25 biomarkers, Aβ1-42, and P-tau181 between the
different cohorts, it was possible to perform the receiver
operating characteristic (ROC) curve analysis and assess
correlations in all patients with Alzheimer’s disease and
controls. ROC curves were performed on each subjectgroup on the tryptic peptides of SNAP-25 in order to as-
sess their diagnostic value. For each tryptic peptide of
SNAP-25 the area under the curve and a 95% confidence
interval was calculated using GraphPad Prism 5. The
correlation coefficients (rho) were calculated using the
Spearman two-tailed correlation test. SPSS 20.0 was
employed for most of the statistical analyses.Ethics
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